Pharmadrug (PHRX) AI Stock Analysis

34 Followers

Pharmadrug

(CNQX:PHRX)

Select Model

Rating:37Underperform

Price Target:CAD 0.01▲(80.00% Upside)

Action:reiterated

Date:09/06/26

Pharmadrug receives the minimum overall score due to critical solvency and operational risks. The company reports zero revenue, deeply negative equity, and persistent cash burn, highlighting severe fundamental weakness. Compounding this is a deeply bearish technical downtrend and a lack of profitability, suggesting an acute risk profile.

Positive Factors

Improved cash burnCash burn has improved materially from prior years, reducing the immediate pace of liquidity depletion. Although cash flow remains negative, a lower burn rate can extend funding runway and create more time for management to improve operations or secure financing.

Negative Factors

No meaningful revenue scaleAn effectively nonexistent revenue base prevents the company from demonstrating product demand, operating scale, or a durable commercial engine. Negative gross profit further suggests current sales do not cover direct costs, leaving fixed expenses and future development dependent on outside funding.

Pharmadrug (PHRX) vs. iShares MSCI Canada ETF (EWC)

Market Cap: CAD 671.07K
Dividend Yield: ―
Average Volume (3M): 6,203
Price to Earnings (P/E): -0.9
Beta (1Y): -1.05
Revenue Growth: ―
EPS Growth: -62.50%
Country: Canada
Employees: 9
Sector: Healthcare
Sector Strength: 51
Industry: Drug Manufacturers - Specialty & Generic

Pharmadrug Business Overview & Revenue Model

Company Description

Pharmadrug Inc., a Toronto-based specialty pharmaceutical firm, is dedicated to the research, development, and market introduction of controlled substances and natural therapeutics, such as psychedelics, cannabis, and other approved compounds derived...

Pharmadrug Financial Statement Overview

Summary

Assigned the minimum score due to severe financial distress, including zero revenue generated over the trailing twelve months, negative equity, and ongoing cash burn, reflecting extreme operational and solvency risks.

Income Statement

10Very Negative

Balance Sheet

8Very Negative

Cash Flow

15Very Negative

Financial statement breakdown
Breakdown	TTM	Mar 2026	Mar 2025	Mar 2024	Mar 2023	Mar 2022
Income Statement
Total Revenue	0	0	0	0	0	7,009
Gross Profit	-50.24K	-50.24K	-50.24K	-26.22K	-2,263	-2,155
EBITDA	-230.10K	-71.98K	-549.04K	-1.33M	-2.34M	-4.21M
Net Income	-641.11K	-383.38K	-793.27K	-13.20M	-8.88M	-5.87M
Balance Sheet
Total Assets	752.22K	551.66K	711.80K	1.20M	12.11M	19.52M
Cash, Cash Equivalents and Short-Term Investments	28.36K	23.24K	75.04K	423.06K	329.24K	1.30M
Total Debt	1.71M	1.52M	1.35M	1.77M	1.42M	866.37K
Total Liabilities	2.46M	2.20M	1.96M	2.66M	3.28M	2.66M
Stockholders Equity	-1.80M	-1.76M	-1.40M	-1.70M	8.84M	16.87M
Cash Flow
Free Cash Flow	-89.56K	-87.51K	-768.60K	-671.88K	-2.26M	-4.17M
Operating Cash Flow	-89.56K	-87.51K	-756.62K	-671.88K	-2.26M	-4.13M
Investing Cash Flow	0	0	-11.98K	995.04K	77.58K	1.48M
Financing Cash Flow	94.86K	0	321.56K	225.51K	843.25K	776.97K

Pharmadrug Technical Analysis

Technical Analysis SentimentNegative

Last Price0.01

Price Trends

50DMA0.01Negative

100DMA0.01Negative

200DMA0.01Negative

Market Momentum

MACD-0.00Negative

RSI45.03Neutral

STOCH0.00Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:PHRX, the sentiment is Negative. The current price of 0.01 is below the 20-day moving average (MA) of 0.01, below the 50-day MA of 0.01, and below the 200-day MA of 0.01, indicating a bearish trend. The MACD of -0.00 indicates Negative momentum. The RSI at 45.03 is Neutral, neither overbought nor oversold. The STOCH value of 0.00 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TSE:PHRX.

Pharmadrug Peers Comparison

Overall Rating

UnderperformOutperform

Sector (51)

Financial Indicators

TSE:PHRX against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
TSE:INNO	41Neutral	CAD 8.19M	-6.15	-19.37%	―	-19.20%	42.54%
TSE:RVV	39Underperform	CAD 8.89M	-16.67	26.78%	―	―	90.84%
TSE:PHRX	37Underperform	CAD 671.07K	-0.93	37.95%	―	―	-62.50%
TSE:RAMM	37Underperform	CAD 1.79M	-0.13	-194.41%	―	-66.40%	31.38%

* Healthcare Sector Average

Performance Comparison

TSE:PHRX and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
TSE:PHRX	Pharmadrug Inc.	0.01	-0.01	-50.00%
TSE:RVV	Revive Therapeutics	0.02	0.01	100.00%
TSE:INNO	Innocan Pharma Corporation	1.82	-14.68	-88.97%
TSE:RAMM	Ramm Pharma Corp	0.01	-0.04	-75.00%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Sep 06, 2026

Pharmadrug AI Stock Analysis